· News · News Desk
Class II recall of multiple Wegovy strengths (0.5 mg/0.5 mL, 1 mg/0.5 mL) for particulate matter remains ongoing nationwide — a reminder that quality defects are not limited to compounded GLP-1 products.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.